Physician profile
Leo Odle
NPI 1073601415
$607.07
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $82.70 · 2021: $211 · 2022: $43.70.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $179.96 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.13 | 2019-2021 | |
| Novo Nordisk INC | $46.28 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $40.79 | 2019-2020 | |
| Abbvie INC. | $40.52 | 2021 | |
| Topcon Healthcare Solutions, INC. | $28.69 | 2019 | |
| Allergan, INC. | $26.27 | 2019-2020 | |
| Nevro Corp. | $21.83 | 2020 | |
| Teleflex LLC | $20.39 | 2021 | |
| Amarin Pharma, INC. | $13.18 | 2019 | |
| Merck Sharp & Dohme LLC | $11.92 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.50 | 2019 | |
| Pfizer INC. | $11.05 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leo Odle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.